MCRB News and Press, Seres Therapeutics Inc. From 05/08/23

– Data from Phase 3 open-label single-arm study of VOWST found nearly 95% of individuals with a clinical response at 8 weeks remained free of CDI through Week 24, regardless of number of prior C. difficile infections (CDI) – – Results from ECOSPOR IV ...

- Company to report initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1 - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 ...

2023-05-03 10:29:02 ET Summary Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first...

– Company to receive proceeds of $110 million upon closing of the agreement – – Financing to support commercial launch of VOWST™ and fund pipeline development – Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics comp...

– First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform – – Phase 3 ECOSPOR III study demonstrated that 88% of treated individuals were recurrence-free at 8 weeks – – Opportunit...

2023-04-22 10:00:52 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-04-21 09:11:40 ET JP Morgan has initiated Seres Therapeutics ( MCRB ) with a neutral rating saying that it will take time for SER-109, currently under priority review with the USA FDA for the prevention of recurrent C. difficile infection, to have its reimbursement to take pl...

2023-04-20 09:45:00 ET After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. Still, scores of beaten-down tech and biotech stocks remain woefully undervalued right now. As a result, there is a s...

2023-04-18 08:33:45 ET BELLUS Health  ( BLU ) +98% surges ~100% after GSK reaches deal to acquire cough drugmaker for ~$2B . Dermata Therapeutics ( DRMA ) +92% . Gamida Cell  ( GMDA ) +42% . Femasys  ( FEMY ) +31% femaSeed local...